Volpara Health Technologies Limited has entered into to a collaboration agreement with Invitae Corporation, to bring Invitae's genetic testing services to Volpara's customers in the United States. Volpara will integrate Invitae into Volpara's software workflow to create additional access for women to comprehensive genetic testing services in different clinical settings. At least one Volpara software product is used with over 32% of women who attend screening each year in the United States.

Customers utilize Volpara's market-leading breast cancer risk assessment software to confidently make informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their personalised risk.